Search
Fortress Biotech Inc
FBIOAdd to Watchlist
2.320USD
-0.020-0.85%
Market hours 09/24, 10:57（ET）
77.07MMarket Cap
0.60P/E TTM
About Fortress Biotech Inc Company
Fortress Biotech, Inc. is a biopharmaceutical company focused on acquiring and advancing assets. The Company has eight marketed prescription pharmaceutical products and over 20 programs in development, with its majority-owned and majority-controlled partners and subsidiaries and partners and subsidiaries it founded and in which it holds significant minority ownership positions. Its portfolio is being commercialized and developed for various therapeutic areas, including oncology, dermatology, and rare diseases. Its dermatology products include Emrosi, Qbrexza, Amzeeq, Zilxi, Exelderm, Targadox, and Luxamend. Its late-stage product candidates include CUTX-101 (copper histidinate injection for Menkes disease), Triplex (cytomegalovirus (CMV) vaccine), and CAEL-101 (monoclonal antibody for AL amyloidosis). Its early and mid-stage product candidates include Dotinurad (urate transporter (URAT1) inhibitor for gout), MB-101 (IL13Rα2 CAR T Cell Program for Glioblastoma), and others.
Fortress Biotech Inc Profile
Ticker SymbolFBIO
Company nameFortress Biotech Inc
IPO dateNov 17, 2011
CEORosenwald (Lindsay A)
Number of employees101
Security typeOrdinary Share
Fiscal year-endNov 17
Address1111 Kane Concourse
CityBAY HARBOR ISLANDS
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code33154
Phone17816524500
Websitehttps://www.fortressbiotech.com/
Ticker SymbolFBIO
IPO dateNov 17, 2011
CEORosenwald (Lindsay A)
Company Executives of Fortress Biotech Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Lindsay A. Rosenwald, M.D.
Dr. Lindsay A. Rosenwald, M.D.
Executive Chairman of the Board, President, Chief Executive Officer
Executive Chairman of the Board, President, Chief Executive Officer
4.59M
--
Dr. Lindsay A. Rosenwald, M.D.
Dr. Lindsay A. Rosenwald, M.D.
Executive Chairman of the Board, President, Chief Executive Officer
Executive Chairman of the Board, President, Chief Executive Officer
4.59M
--
Dr. Lindsay A. Rosenwald, M.D.
Dr. Lindsay A. Rosenwald, M.D.
Executive Chairman of the Board, President, Chief Executive Officer
Executive Chairman of the Board, President, Chief Executive Officer
4.59M
--
Mr. Michael S. Weiss, J.D.
Mr. Michael S. Weiss, J.D.
Executive Vice Chairman - Strategic Development, Director
Executive Vice Chairman - Strategic Development, Director
2.28M
--
Mr. Michael S. Weiss, J.D.
Mr. Michael S. Weiss, J.D.
Executive Vice Chairman - Strategic Development, Director
Executive Vice Chairman - Strategic Development, Director
2.28M
--
Mr. Michael S. Weiss, J.D.
Mr. Michael S. Weiss, J.D.
Executive Vice Chairman - Strategic Development, Director
Executive Vice Chairman - Strategic Development, Director
2.28M
--
Mr. David Jin
Mr. David Jin
Chief Financial Officer and Head of Corporate Development
Chief Financial Officer and Head of Corporate Development
421.57K
+94.88%
Mr. David Jin
Mr. David Jin
Chief Financial Officer and Head of Corporate Development
Chief Financial Officer and Head of Corporate Development
421.57K
+94.88%
Mr. David Jin
Mr. David Jin
Chief Financial Officer and Head of Corporate Development
Chief Financial Officer and Head of Corporate Development
421.57K
+94.88%
Mr. Dov Klein, CPA
Mr. Dov Klein, CPA
Independent Director
Independent Director
130.10K
+57.91%
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Lindsay A. Rosenwald, M.D.
Dr. Lindsay A. Rosenwald, M.D.
Executive Chairman of the Board, President, Chief Executive Officer
Executive Chairman of the Board, President, Chief Executive Officer
4.59M
--
Dr. Lindsay A. Rosenwald, M.D.
Dr. Lindsay A. Rosenwald, M.D.
Executive Chairman of the Board, President, Chief Executive Officer
Executive Chairman of the Board, President, Chief Executive Officer
4.59M
--
Dr. Lindsay A. Rosenwald, M.D.
Dr. Lindsay A. Rosenwald, M.D.
Executive Chairman of the Board, President, Chief Executive Officer
Executive Chairman of the Board, President, Chief Executive Officer
4.59M
--
Mr. Michael S. Weiss, J.D.
Mr. Michael S. Weiss, J.D.
Executive Vice Chairman - Strategic Development, Director
Executive Vice Chairman - Strategic Development, Director
2.28M
--
Mr. Michael S. Weiss, J.D.
Mr. Michael S. Weiss, J.D.
Executive Vice Chairman - Strategic Development, Director
Executive Vice Chairman - Strategic Development, Director
2.28M
--
Mr. Michael S. Weiss, J.D.
Mr. Michael S. Weiss, J.D.
Executive Vice Chairman - Strategic Development, Director
Executive Vice Chairman - Strategic Development, Director
2.28M
--
FAQs
Who are the top five shareholders of Fortress Biotech Inc?
The top five shareholders of Fortress Biotech Inc are: Dr. Lindsay A. Rosenwald, M.D.
How many institutions hold shares of Fortress Biotech Inc (FBIO)?
As of 2026Q1, 113 institutions hold shares of Fortress Biotech Inc, with a combined market value of approximately 6.02M, accounting for 18.14% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -871667.00.
What is the biggest source of revenue for Fortress Biotech Inc?
In 2026Q1, the Targadox® business generated the highest revenue for Fortress Biotech Inc, amounting to 3.20M and accounting for 3.79% of total revenue.